EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

N Lamichhane, N Melas, V Bergqvist, SWIBREG, N-P Ekholm, O Olén, J F Ludvigsson, H Hjortswang, J Marsal, C Eriksson, J Halfvarson

Digestive Diseases and Sciences · 2024-06 · 69 (6) · 2175-2183

DOI: 10.1007/s10620-024-08422-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, online erschienen am 18.04.2024. Verfasst von N Lamichhane und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Health and Medical Sciences, Örebro University, Örebro, Sweden. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Quality of Life, Colitis, Ulcerative. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharmaceuticals AB, Örebro University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsQuality of LifeColitis, UlcerativeCrohn DiseaseHumansFemaleMaleAdultMiddle AgedInjections, SubcutaneousTreatment OutcomeAdministration, IntravenousRegistriesInflammatory Bowel DiseasesLeukocyte L1 Antigen ComplexSwedenDrug SubstitutionRemission Induction

Stichwörter der Autor:innen

Inflammatory bowel diseaseObservational studyReal-world dataVedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • School of Health and Medical Sciences, Örebro University, Örebro, Sweden.
  • Central Hospital in Karlstad, Karlstad, Sweden.
  • Department of Gastroenterology, Skåne University Hospital, Lund, Sweden.
  • Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Takeda Pharma, Medical Affairs, Stockholm, Sweden.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Förderung

  • Takeda Pharmaceuticals AB
  • Örebro University

Zitieren

APA

Lamichhane, N., Melas, N., Bergqvist, V., SWIBREG, Ekholm, N. P., Olén, O., Ludvigsson, J. F., Hjortswang, H., Marsal, J., Eriksson, C., & Halfvarson, J. (2024). Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 69(6), 2175-2183. https://doi.org/10.1007/s10620-024-08422-9

Vancouver

Lamichhane N, Melas N, Bergqvist V, SWIBREG, Ekholm NP, Olén O, et al. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences. 2024;69(6):2175-2183. doi:10.1007/s10620-024-08422-9

BibTeX
@article{Lamichhane2024,
  author = {Lamichhane, N and Melas, N and Bergqvist, V and SWIBREG, SWIBREG and Ekholm, N-P and Olén, O and Ludvigsson, J F and Hjortswang, H and Marsal, J and Eriksson, C and Halfvarson, J},
  title = {Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease},
  journal = {Digestive Diseases and Sciences},
  year = {2024},
  volume = {69},
  number = {6},
  pages = {2175--2183},
  doi = {10.1007/s10620-024-08422-9}
}
Kostenlos starten →